AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20137366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with sufentanil 0.5 microg/ml
Number of subjects: 450
Study 20137366 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine with sufentanil 0.5 microg/ml
Number of subjects: 450
Study 20137366 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% concentration of bupivacaine, ropivacaine, and levobupivacaine
Number of subjects: 450
Study 17442997 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 with bevacizumab
Number of subjects: 829
Study 17442997 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 without bevacizumab
Number of subjects: 829
Study 17442997 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 829
Study 15604328 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 4 weeks
Number of subjects: 35
Study 15604328 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin)
Number of subjects: 35
Study 11948384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogen circumcision
Number of subjects: 59
Study 11948384 — intervention group
Group type: COMPARATOR
Intervention: PlastiBell circumcision
Number of subjects: 59
Study 10554373 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy (24 hours)
Number of subjects: 63
Study 10554373 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-course antibiotic therapy (5 days)
Number of subjects: 63
Study 8556837 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta administered subcutaneously either daily or thrice weekly
Number of subjects: 266
Study 1789812 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (2.5 to 40 mg q.p.m.)
Number of subjects: 15
Study 7326162 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl anaesthesia (75 micrograms kg‐1)
Number of subjects: 0
Study 7326162 — intervention group
Group type: COMPARATOR
Intervention: Incremental doses of papaveretum
Number of subjects: 0
Study 31808268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 31808268 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 31808268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31808268 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG connectivity metrics
Number of subjects: 0
Study 31808268 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG and fMRI
Number of subjects: 0
Study 31229857 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-D (5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 103
Study 31229857 — intervention group
Group type: COMPARATOR
Intervention: TC6 (docetaxel and cyclophosphamide)
Number of subjects: 103
Study 31229857 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-D
Number of subjects: 103
Study 31229857 — intervention group
Group type: COMPARATOR
Intervention: TC6
Number of subjects: 103
Study 28384752 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of NP001
Number of subjects: 394
Study 28384752 — intervention group
Group type: COMPARATOR
Intervention: Normal baseline CRP receiving NP001 or placebo
Number of subjects: 394
Study 28384752 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 394
Study 28384752 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels in independent cohort
Number of subjects: 394
Study 26513587 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (20mg)
Number of subjects: 24
Study 26513587 — intervention group
Group type: COMPARATOR
Intervention: alcohol (0.8 g/kg)
Number of subjects: 24
Study 26513587 — intervention group
Group type: COMPARATOR
Intervention: delta-9-tetrahydrocannabinol (THC) (7.5 mg)
Number of subjects: 24
Study 26513587 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 23968797 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD training
Number of subjects: 75
Study 23968797 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 75
Study 21297491 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 112
Study 21297491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 19699834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake among obese employees
Number of subjects: 373
Study 19699834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean daily energy intake
Number of subjects: 373
Study 19699834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat recommendations compliance
Number of subjects: 373
Study 19699834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber intake compliance
Number of subjects: 373
Study 19699834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake
Number of subjects: 373
Study 19699834 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grains intake
Number of subjects: 373
Study 19699834 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPyramid recommendations compliance for fruits or vegetables
Number of subjects: 373
Study 19699834 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPyramid recommendations compliance for milk and dairy foods
Number of subjects: 373
Study 18005291 — intervention group
Group type: EXPERIMENTAL
Intervention: Health library and information services
Number of subjects: 0
Study 18005291 — intervention group
Group type: EXPERIMENTAL
Intervention: Health sciences library research methods
Number of subjects: 0
Study 18005291 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based library and information practice
Number of subjects: 0
Study 18005291 — intervention group
Group type: EXPERIMENTAL
Intervention: Value and impact studies
Number of subjects: 0
Study 15099130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-process theory (DPT)
Number of subjects: 0
Study 15099130 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-detection theory (SDT)
Number of subjects: 0
Study 11230880 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 0
Study 11230880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9754848 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tolperisone hydrochloride
Number of subjects: 72
Study 9754848 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg tolperisone hydrochloride
Number of subjects: 72
Study 9754848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8850405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (group A)
Number of subjects: 34
Study 8850405 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 34
Study 2651226 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical anterior oesophagomyotomy by abdominal route
Number of subjects: 81
Study 2651226 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilatation with the Mosher bag
Number of subjects: 81
Study 579654 — intervention group
Group type: EXPERIMENTAL
Intervention: Holoxan therapy
Number of subjects: 47
Study 579654 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 47
Study 30221615 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS-START intervention (six-session manualized therapy)
Number of subjects: 95
Study 30221615 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS-START intervention
Number of subjects: 95
Study 30221615 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (control)
Number of subjects: 95
Study 27558500 — intervention group
Group type: EXPERIMENTAL
Intervention: online behavioural training (oBT)
Number of subjects: 178
Study 27558500 — intervention group
Group type: COMPARATOR
Intervention: watchful waiting (control group)
Number of subjects: 178
Study 26270953 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO (robotic animal)
Number of subjects: 380
Study 26270953 — intervention group
Group type: EXPERIMENTAL
Intervention: Plush‐Toy (non‐robotic PARO)
Number of subjects: 380
Study 26270953 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 380
Study 26270953 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO or Plush‐Toy
Number of subjects: 380
Study 24033650 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized aphasia therapy
Number of subjects: 24
Study 24033650 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 21876444 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed lopinavir/ritonavir tablets (200/50 mg)
Number of subjects: 12
Study 21876444 — intervention group
Group type: COMPARATOR
Intervention: Whole lopinavir/ritonavir tablets (200/50 mg)
Number of subjects: 12
Study 19682886 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE analgesia with bupivacaine 2.5mg and fentanyl 15 microg
Number of subjects: 96
Study 19682886 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl 50 microg
Number of subjects: 96
Study 19682886 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE analgesia
Number of subjects: 96
Study 19682886 — intervention group
Group type: COMPARATOR
Intervention: SYS group (Intravenous fentanyl 50 microg)
Number of subjects: 96
Study 19682886 — intervention group
Group type: COMPARATOR
Intervention: SYS analgesia
Number of subjects: 96
Study 16939523 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐Intron 3‐6 microg kg(‐1) administered subcutaneously once a week
Number of subjects: 137
Study 16939523 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐Intron 6.0 microg kg(‐1) week(‐1)
Number of subjects: 137
Study 16939523 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐Intron in patients with CML
Number of subjects: 137
Study 15472204 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenoate (200 mg injections)
Number of subjects: 12
Study 15472204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11576570 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 155
Study 11576570 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone-containing pills
Number of subjects: 155
Study 11576570 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing pills
Number of subjects: 155
Study 11576570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal contraception)
Number of subjects: 155
Study 9755734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 369
Study 9755734 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 369
Study 7529657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast cell counts in osteoporotic individuals
Number of subjects: 24
Study 7529657 — intervention group
Group type: COMPARATOR
Intervention: Mast cell counts in normal individuals
Number of subjects: 24
Study 7529657 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of ovoid mast cells in osteoporotic individuals
Number of subjects: 24
Study 7529657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast cell counts in systemic mastocytosis
Number of subjects: 24
Study 3503390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of OK-432 (ID Group)
Number of subjects: 121
Study 3503390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of OK-432 (IM Group)
Number of subjects: 121
Study 3503390 — intervention group
Group type: COMPARATOR
Intervention: Control group (C Group)
Number of subjects: 121
Study 31388792 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-101 (40 mg) every 12 h on days 1, 2, and 3 combined with paclitaxel (150 mg/m2) and carboplatin (AUC 5) at DL1
Number of subjects: 24
Study 31388792 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-101 (40 mg) every 12 h on days 1, 2, and 3 combined with paclitaxel (175 mg/m2) and carboplatin (AUC 6) at DL2
Number of subjects: 24
Study 29398304 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Therapeutic Play Education Program
Number of subjects: 43
Study 29398304 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 28838582 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 39
Study 28838582 — intervention group
Group type: COMPARATOR
Intervention: Community care (COM)
Number of subjects: 39
Study 26607848 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg total: two 40 mg capsules 1 hour prior to extraction and one 40 mg capsule postoperatively)
Number of subjects: 34
Study 26607848 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg total)
Number of subjects: 34
Study 26607848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24047916 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet (≥90 g protein/d)
Number of subjects: 323
Study 21493931 — intervention group
Group type: EXPERIMENTAL
Intervention: Malawi Male Motivator intervention
Number of subjects: 400
Study 21493931 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 400
Study 19515530 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ISDN in Vaseline applied to the dorsum of the affected hand four times daily for 10 weeks
Number of subjects: 24
Study 19515530 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied to the dorsum of the affected hand four times daily for 10 weeks
Number of subjects: 24
Study 16826385 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CPR
Number of subjects: 0
Study 16826385 — intervention group
Group type: EXPERIMENTAL
Intervention: Backboard CPR
Number of subjects: 0
Study 16826385 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling on the bed
Number of subjects: 0
Study 16826385 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering bed height
Number of subjects: 0
Study 15220683 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors, H2‐receptor antagonists, prokinetics, or antacids (specifics not detailed)
Number of subjects: 185
Study 15220683 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic procedures (specifics not detailed)
Number of subjects: 185
Study 15220683 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy with proton pump inhibitors, H2‐receptor antagonists, prokinetics, or antacids
Number of subjects: 185
Study 11069315 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment for active ulcerative colitis
Number of subjects: 25
Study 11069315 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 11069315 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to treatment
Number of subjects: 25
Study 9351415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users
Number of subjects: 819
Study 9351415 — intervention group
Group type: COMPARATOR
Intervention: Non-users of oral contraceptives
Number of subjects: 819
Study 9351415 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes (both users and non-users)
Number of subjects: 819
Study 1327630 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated computerized program using Finapres for measuring cardiovascular reflexes
Number of subjects: 10
Study 1327630 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated computerized program using Finapres
Number of subjects: 10
Study 2866830 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 10 mg
Number of subjects: 190
Study 2866830 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 15 mg
Number of subjects: 190
Study 2866830 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 190
Study 2866830 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 5 mg
Number of subjects: 190
Study 2866830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 30548692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day plus solifenacin 5 mg, propiverine 20 mg, imidafenacin 0.2 mg, or tolterodine 4 mg (with potential to double the antimuscarinic dose at week 8)
Number of subjects: 100
Study 30548692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day plus antimuscarinic therapy
Number of subjects: 100
Study 30548692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day plus propiverine
Number of subjects: 100
Study 30548692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day plus tolterodine
Number of subjects: 100
Study 29450494 — intervention group
Group type: EXPERIMENTAL
Intervention: ROR (Oncotype Dx recurrence score)
Number of subjects: 774
Study 29450494 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI (Breast Cancer Index)
Number of subjects: 774
Study 29450494 — intervention group
Group type: EXPERIMENTAL
Intervention: EPclin (EndoPredict)
Number of subjects: 774
Study 29450494 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Treatment Score
Number of subjects: 774
Study 29450494 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence score (Oncotype Dx)
Number of subjects: 774
Study 29450494 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-marker immunohistochemical score
Number of subjects: 774
Study 29450494 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI (Breast Cancer Index) for patients with 1 to 3 positive nodes
Number of subjects: 774
Study 29450494 — intervention group
Group type: EXPERIMENTAL
Intervention: EPclin (EndoPredict) for patients with 1 to 3 positive nodes
Number of subjects: 774
Study 26714439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented green tea
Number of subjects: 60
Study 26714439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hot water)
Number of subjects: 60
Study 24568917 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP)
Number of subjects: 42
Study 24568917 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 42
Study 21751267 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya milk intervention for 5 days
Number of subjects: 40
Study 19558724 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing treatment
Number of subjects: 1804
Study 19558724 — intervention group
Group type: COMPARATOR
Intervention: Memory treatment
Number of subjects: 1804
Study 19558724 — intervention group
Group type: COMPARATOR
Intervention: Reasoning treatment
Number of subjects: 1804
Study 19558724 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 1804
Study 17598717 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with epinephrine at 1:200 000
Number of subjects: 30
Study 17598717 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study 15225189 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micro g misoprostol sublingually
Number of subjects: 60
Study 15225189 — intervention group
Group type: COMPARATOR
Intervention: 1 ml syntometrine intravenously
Number of subjects: 60
Study 12237651 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic hematuria
Number of subjects: 4307
Study 12237651 — intervention group
Group type: COMPARATOR
Intervention: No idiopathic hematuria (Control)
Number of subjects: 4307
Study 9698276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin-rich plant extract from Gossypium herbaceum
Number of subjects: 0
Study 9698276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7641723 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 105
Study 7641723 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 105
Study 7641723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 105
Study 7641723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 2681086 — intervention group
Group type: EXPERIMENTAL
Intervention: Anandron 300 mg daily
Number of subjects: 51
Study 2681086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 999991 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive hypnosis
Number of subjects: 2
Study 999991 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggested environmental conditions of cold and heat in hypnosis
Number of subjects: 2
Study 999991 — intervention group
Group type: COMPARATOR
Intervention: Resting awake condition
Number of subjects: 2
Study 30525956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter with misoprostol
Number of subjects: 1306
Study 30525956 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 1306
Study 28946528 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF treatment
Number of subjects: 80
Study 28946528 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy (MAN.T)
Number of subjects: 80
Study 26401941 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH meal (50% total fat, 25% saturated fat, glycemic index >70)
Number of subjects: 46
Study 26401941 — intervention group
Group type: COMPARATOR
Intervention: LOW meal (25% total fat, 7% saturated fat, glycemic index <55)
Number of subjects: 46
Study 26401941 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH meal
Number of subjects: 46
Study 23038624 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg for 1 week
Number of subjects: 20
Study 23038624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21804104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose, 90 mg twice daily)
Number of subjects: 18421
Study 21804104 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300-600 mg loading dose, 75 mg daily)
Number of subjects: 18421
Study 21804104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18421
Study 21804104 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18421
Study 19538732 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/day, orally, for 12 months)
Number of subjects: 110
Study 19538732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 17055863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pull sphincterotome
Number of subjects: 48